Document Detail


Changes in the activity of the GPx-1 anti-oxidant selenoenzyme in mononuclear cells following imatinib treatment.
MedLine Citation:
PMID:  21292323     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Imatinib inhibits the ABL tyrosine kinase and is effective for the treatment of chronic myeloid leukemia (CML). ABL activates GPx-1, an enzyme associated with protection against oxidative DNA damage and disease. Enzyme activity was assessed in sample pairs consisting of mononuclear cells obtained from patients before and after imatinib therapy. Control sample sets obtained from patients not receiving imatinib showed little change in GPx activity over a several month interval. Five of 7 sample sets obtained from imatinib-receiving patients showed changes in GPx activity greater than 30%. One sample decreased 42% while 4 others increased 33-208%. Patients with the largest increase in activity were female and had the lowest baseline levels of GPx activity. Changes in GPx activity may influence the clinical outcome of patients being treated for CML.
Authors:
Emily N Terry; Peter H Gann; Robert Molokie; Michael Deininger; Alan M Diamond
Related Documents :
3571943 - A pilot study of combined trazodone and tryptophan in obsessive-compulsive disorder.
474173 - Family-size and birth-order in obsessional neurosis.
12168323 - Shunt testing in-vivo: a method based on the data from the uk shunt evaluation laboratory.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2011-02-02
Journal Detail:
Title:  Leukemia research     Volume:  35     ISSN:  1873-5835     ISO Abbreviation:  Leuk. Res.     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-09-13     Completed Date:  2011-12-07     Revised Date:  2014-09-21    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  831-3     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Benzamides
Cell Line, Tumor
Cells, Cultured
Female
Glutathione Peroxidase / metabolism*
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*,  enzymology,  pathology
Leukocytes, Mononuclear / drug effects*,  enzymology
Male
Middle Aged
Piperazines / therapeutic use*
Protein Kinase Inhibitors / therapeutic use
Pyrimidines / therapeutic use*
Treatment Outcome
Grant Support
ID/Acronym/Agency:
1R21CA129590/CA/NCI NIH HHS; R01HL082978/HL/NHLBI NIH HHS; R21 CA129590/CA/NCI NIH HHS; R21 CA129590-02/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Benzamides; 0/Piperazines; 0/Protein Kinase Inhibitors; 0/Pyrimidines; BKJ8M8G5HI/imatinib; EC 1.11.1.-/glutathione peroxidase GPX1; EC 1.11.1.9/Glutathione Peroxidase
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Upregulation of growth signaling and nutrient transporters in cotyledons of early to mid-gestational...
Next Document:  Inhibition of mouse TAP by immune evasion molecules encoded by non-murine herpesviruses.